Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of atacicept in methotrexate-inadequate-response rheumatoid arthritis
2007-002536-29Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Oct 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atacicept in rheumatoid arthritis (RA) (3 arms), sponsored by Merck Serono. Primary endpoint: ACR20 response at Week 26. Started Oct 2007; status: completed.
02
Drugs
atacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-002536-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002536-29.